Convatec GroupLSE:CTEC +1.15%77 EBITDA Margin % is 18.97% as of Dec. 2025, which is 11% below its 10-year median of 21.21. GuruFocus rates LSE:CTEC with a GF Score™ of 77/100 and a GF Value™ of £2.55 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Convatec Group ranks better than 77.45% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Convatec Group's EBITDA for the
six
months ended in Dec. 2025 was £178 Mil. Convatec Group's Revenue for the
six
months ended in Dec. 2025 was £941 Mil. Therefore, Convatec Group's EBITDA margin for the quarter that ended in Dec. 2025 was 18.97%.
Convatec Group (LSE:CTEC) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Convatec Group EBITDA Margin % Related Terms
Convatec Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Convatec Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:CTEC vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Convatec Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Convatec Group EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Convatec Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Convatec Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Convatec Group (LSE:CTEC) has a EBITDA Margin % of 18.97% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Convatec Group and its competitors. This is 11% below median its historical median of 21.21. Over the past decade, Convatec Group's EBITDA Margin % has ranged from 16.00 to 24.84. According to the industry distribution chart, Convatec Group ranks #184 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 22.5%.
Is Convatec Group's EBITDA Margin % too high?
Convatec Group's current EBITDA Margin % of 18.97% is 11% below median its 10-year median of 21.21. Over the past 10 years, this metric has ranged from a low of 16.00 to a high of 24.84. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Convatec Group's value of 18.97% is 153.8% above this industry median. Based on the distribution chart, Convatec Group ranks #184 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Convatec Group has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Convatec Group's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Convatec Group ranks #184 out of 816 companies for EBITDA Margin %. This places Convatec Group in the top 23% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Convatec Group's value of 18.97% is 153.8% above this benchmark. Historically, Convatec Group's own EBITDA Margin % has ranged from 16.00 to 24.84 over the past decade. While the company's 10-year median is 21.21 vs. the industry median of 7.48, Convatec Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Convatec Group's current EBITDA Margin % of 18.97% is 153.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Convatec Group and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Convatec Group's current EBITDA Margin % is 18.97%, which is 11% below median its own 10-year median of 21.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Convatec Group stock overvalued right now?
Based on GuruFocus' analysis, Convatec Group (LSE:CTEC) is currently considered Modestly Undervalued. The stock's GF Value™ is £2.55, compared to a current price of £2.12 — trading 16.9% below its estimated fair value. The current EBITDA Margin % is 18.97%, which is 11% below median its 10-year median of 21.21 and 153.8% above the Medical Devices & Instruments industry median of 7.48. Convatec Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Convatec Group (LSE:CTEC), the current EBITDA Margin % is 18.97% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Convatec Group (LSE:CTEC) Overvalued in 2026?
Based on GuruFocus' analysis, Convatec Group stock appears to be undervalued.
The current stock price of £2.12 is trading 16.9% below its estimated GF Value™ of £2.55.
GuruFocus considers Convatec Group to be Modestly Undervalued.
Key valuation signals for LSE:CTEC:
EBITDA Margin %: 18.97% (11% below median its 10-year median of 21.21)
GF Value™: £2.55 vs. price of £2.12 (16.9% below fair value)
Industry Position: 153.8% above the Medical Devices & Instruments median (#184 of 816)
No single metric tells the full story. See the LSE:CTEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
77GF Score
Get the complete analysis for LSE:CTEC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:CTEC has been successfully added to your 
